Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Healthtrust
Teva
QuintilesIMS
McKesson
Johnson and Johnson
UBS
Queensland Health

Generated: February 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MIRTAZAPINE

« Back to Dashboard

Clinical Trials for Mirtazapine

Trial ID Title Status Sponsor Phase Summary
NCT00021528 Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Completed National Institute of Mental Health (NIMH) Phase 4 STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
NCT00108498 New Pharmacological Treatment for Obstructive Sleep Apnea Completed VA Office of Research and Development Phase 1 This study will determine if mirtazapine, a unique antidepressant that does not disturb sleep, will improve obstructive sleep apnea (OSA). The design is randomized, crossover, double blind, and placebo controlled. On two consecutive nights of one week, the patients receive either 30 mg mirtazapine or placebo at bedtime. The following week, the alternative medication is administered. The patients have known mild to moderate sleep apnea. The endpoints of the study are the apnea + hypopnea index (AHI), sleep quality, and the degree of arterial oxygen desaturation.
NCT00150839 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status University of Erlangen-N├╝rnberg Phase 4 The proposed study is a randomized, placebo-controlled, double-blind trial to evaluate the safety and efficacy of antidepressant combination for the treatment of depression. Depressive disorder is one of the most common human diseases with a high burden for every patient, her/his family, health care system and society as a whole. Actual treatment concepts of depressive disorders include pharmacologic, biologic (e.g. electroconvulsive therapy, light therapy) and psychologic therapy. Even though effective therapeutic options are at hand, therapy needs time. It is often not possible to reach full remission of the disease and 10-25% of patients suffering from depression are regarded as "treatment-resistant". In treatment resistant depression, the use of a combination of antidepressive drugs is considered safe and effective. However, at present no data exist concerning the use of drug combination as primary therapeutic option. The aim of the study is to examine the hypothesis, that significantly more patients achieve full remission of depressive symptoms when treated with the combination of two antidepressants and as a secondary hypothesis, that patients receiving a drug combination will achieve remission faster than patients treated with monotherapy. To test these hypotheses, a two group parallel design is used comparing the efficacy and safety of mirtazapine in combination with venlafaxine or placebo.
NCT00249444 Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression Completed National Institute on Drug Abuse (NIDA) Phase 2 Many substance dependent individuals also suffer from depression. Past research suggests that antidepressant medication is helpful in treating such individuals. This study will determine the effectiveness of mirtazapine, an antidepressant medication, in treating cocaine dependent individuals who also suffer from depression. This study includes free treatment for cocaine dependence that includes medication and a behavioral intervention.
NCT00249444 Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression Completed New York State Psychiatric Institute Phase 2 Many substance dependent individuals also suffer from depression. Past research suggests that antidepressant medication is helpful in treating such individuals. This study will determine the effectiveness of mirtazapine, an antidepressant medication, in treating cocaine dependent individuals who also suffer from depression. This study includes free treatment for cocaine dependence that includes medication and a behavioral intervention.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Mirtazapine

Condition Name

Condition Name for Mirtazapine
Intervention Trials
Major Depressive Disorder 11
Depression 11
Healthy 6
Anorexia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mirtazapine
Intervention Trials
Depression 29
Depressive Disorder 24
Depressive Disorder, Major 18
Disease 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mirtazapine

Trials by Country

Trials by Country for Mirtazapine
Location Trials
United States 80
China 10
Germany 6
Korea, Republic of 4
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mirtazapine
Location Trials
North Carolina 6
Alabama 6
Texas 6
Pennsylvania 6
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mirtazapine

Clinical Trial Phase

Clinical Trial Phase for Mirtazapine
Clinical Trial Phase Trials
Phase 4 20
Phase 3 13
Phase 2/Phase 3 2
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mirtazapine
Clinical Trial Phase Trials
Completed 37
Recruiting 10
Unknown status 7
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mirtazapine

Sponsor Name

Sponsor Name for Mirtazapine
Sponsor Trials
National Institute on Drug Abuse (NIDA) 4
VA Office of Research and Development 3
National Institute of Mental Health (NIMH) 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mirtazapine
Sponsor Trials
Other 92
Industry 17
NIH 8
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Dow
Queensland Health
Fuji
Merck
Chinese Patent Office
Colorcon
Boehringer Ingelheim
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.